Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10185016 | 1.00 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10184403 | 0.92 | DGAT1 (0.54) | ALDH1A1L3MBTL1DGAT1HRH3MEN1 | |
| SCHEMBL10185119 | 0.92 | NPC1 (0.56) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10184440 | 0.91 | NPC1 (0.49) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10184899 | 0.90 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2MAPTHPGD | |
| SCHEMBL10185184 | 0.90 | NPC1 (0.48) | RAB9ANPC1SMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL10185185 | 0.89 | NPC1 (0.50) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10185149 | 0.89 | DGAT1 (0.50) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10185047 | 0.89 | NPC1 (0.55) | RAB9ANPC1SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL10185044 | 0.89 | LMNA (0.54) | NPC1L3MBTL1DGAT1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | RAB9A 1660/4885NPC1 201/4885SMN1; SMN2 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.